Cadila Healthcare enters into a settlement and license agreement with Somaxon for Silenor

Cadila Healthcare enters into a settlement and license agreement with Somaxon for Silenor® Ahmedabad, July 19, 2012 Cadila Healthcare Limited, a global pharmaceutical company, and Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, today announced that they have entered into a settlement and license agreement with Somaxon Pharmaceuticals, Inc. and ProCom One to resolve pending patent litigation involving Silenor® (Doxepin) 3 mg and 6 mg tablets. Under the settlement and license agreement, Cadila Healthcare and Zydus Pharmaceuticals (USA) Inc., have the right to begin selling a generic version of Silenor 180 days after another party begins selling a generic version of Silenor in the United States under a license from Somaxon, 180 days after a United States court enters a final decision that Somaxon's patents are not infringed, invalid or unenforceable, or earlier under certain circumstances. ###

The release as fetched from its publisher. zyduslife.com ↗